A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients

Journal of Pharmacological Sciences

Volumn 97, Issue 4, 2005, Pages 489-493

  Hermida, Jesús ^a   Tutor, J Carlos ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Dose adjustment; Hypoalbuminemia; Ultrafiltration; Valproic acid

Indexed keywords

ALBUMIN; CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; HUMAN; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; THEORETICAL STUDY;

EID: 18244379834     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FPE04007X     Document Type: Article

References (18)

1. Kwong TC. Free drug measurements: methodology and clinical significance. Clin Chim Acta. 1985;151:193-216.
2. Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med. 2002;40:986-993.
3. Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med. 1999;123:822-823.
4. DeVane L. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol Bull. 2002;36:1-25.
5. Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. Clin Chem. 1998;44:1085-1095.
6. Lenn NJ, Robertson M. Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy. Neurology. 1992;42:988-990.
7. Levy RH. Monitoring of free valproic acid levels? Ther Drug Monit. 1980;2:199-201.
8. Gidal BE, Collins DM, Beinlich BR. Apparent valproic acid neurotoxicity in a hypoalbumineraic patient. Ann Pharmacother. 1993;27:32-35.
9. Haraldson JA, Kramer LE, Wolff DL, Lake KD. Elevated free, fractions of valproic acid in a heart transplant patient with hypoalbuminemia. Ann Pharmacother. 2000;34:183-186.
10. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Clin Pharmacokinet. 1999;36:453-470.
11. Kodama Y, Kuranari M, Kodama H, Koike Y, Yasunaga F, Fujii I, et al. Evaluation of binding equation method for prediction of unbound serum valproic acid concentration in pediatric patients with epilepsy. Int J Clin Pharmacol Ther. 1995;33:114-118.
12. Kodama Y, Kuranari M, Kodama H, Ashikari Y, Fujii I, Takeyama M. Evaluation of binding equation method for unbound serum concentration prediction of valproic acid in polytherapy pediatric pateints with epilepsy. Am J Ther. 1995;2:106-111.
13. Kodama Y, Kuranari M, Kodama H, Zaizen T, Yukawa E, Fujii I, et al. Comparison of two binding equations for prediction of the concentration of unbound valproic acid in the serum of adult epileptic polytherapy patients. J Pharm Pharmacol. 1996;48:1068-1072.
14. Parent X, Marzullo C, Gutbub AM. [Valproic acid: a simple method for the estimation of free serum concentration.] Ann Biol Clin (Paris). 1993;51:649-650. (text in French)
15. Herbeth B. Albumine. In: Siest G, Henny J, Schiele F, editors. Références en biologie clinique. Amsterdam: Elsevier; 1990. p. 93-106. (text in French)
16. Liu H, Montoya JL, Forman LJ, Eggers CM, Barham CF, Delgado M. Determination of free valproic acid: evaluation of the Centrifree system and comparison between high-performance liquid chromatography and enzyme immunoassay. Ther Drug Monit. 1992;14:513-521.
17. Pinnell AE, Northam BE. New automated dye-binding method for serum albumin determination with bromocresol purple. Clin Chem. 1978;24:80-86.
18. Bailey DN, Briggs JR. The binding of selected therapeutic drugs to human serum α-1 acid glycoprotein and human serum albumin in vitro. Ther Drug Monit. 2004;26:40-43.